Evidence map›Paper›PMID 25618012›Full record

ArticleAnnals of nuclear medicine2015

High-uptake areas on positron emission tomography with the hypoxic radiotracer (18)F-FRP170 in glioblastomas include regions retaining proliferative activity under hypoxia.

Takaaki Beppu, Toshiaki Sasaki, Kazunori Terasaki, Hiroaki Saura, Hideki Mtsuura, Kuniaki Ogasawara, Makoto Sasaki, Shigeru Ehara, Ren Iwata, Yoshihiro Takai

Open access · hybridAbstract read
In one paragraph

Article in Annals of nuclear medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Introduction of nuclear medicine research in Japan.European journal of nuclear medicine and molecular imaging · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Takaaki BeppuDepartment of Neurosurgery, Iwate Medical University, Uchimaru 19-1, Morioka, 020-8505, Japan, tbeppu@iwate-med.ac.jp.
Toshiaki Sasaki
Kazunori Terasaki
Hiroaki Saura
Hideki Mtsuura
Kuniaki Ogasawara
Makoto Sasaki
Shigeru Ehara
Ren Iwata
Yoshihiro Takai
Iwate Medical University · JPHirosaki University · JPTohoku University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe aim was to evaluate the proliferative activity of high-uptake areas on positron emission tomography (PET) with the hypoxic cell radiotracer, 1-(2-[(18)F]fluoro-1-[hydroxymethyl]ethoxy)methyl-2-nitroimidazole (FRP170).

methodsThirteen patients with glioblastoma underwent FRP170 PET before tumor resection. During surgery, tumor specimens were stereotaxically obtained from regions corresponding to high (high-uptake areas, HUAs) and relatively low (low-uptake areas, LUAs) accumulation of FRP170. We compared immunohistochemical staining for Ki-67 and hypoxia-inducible factor (HIF)-1α between HUA and LUA.

resultsHIF-1α index was significantly higher in HUAs than in LUAs. In contrast, mean Ki-67 indices did not differ significantly between HUAs and LUAs.

conclusionsFindings for HIF-1α index clearly indicated that HUAs on FRP170 PET represented hypoxic regions in glioblastoma. However, findings of Ki-67 index suggest that HUAs on FRP170 PET include regions retaining proliferative activity regardless of tissue hypoxia.

Indexed as

NitroimidazolesPositron-Emission TomographyRadiopharmaceuticalsAdultAgedBrainBrain NeoplasmsFemaleGlioblastomaHumansHypoxiaHypoxia-Inducible Factor 1, alpha SubunitImmunohistochemistryKi-67 AntigenMaleMiddle AgedFRP-170HIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitKi-67 AntigenNitroimidazolesRadiopharmaceuticals

Identifiers

PMID25618012
PMCPMC4661197
OpenAlexW2049854128

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.